About Bluepha
Bluepha is a company based in Beijing (China) founded in 2016. Bluepha has raised $133.02 million across 8 funding rounds from investors including SVB, China Merchants Bank and China Renaissance Group. Bluepha operates in a competitive market with competitors including Amyris, Inscripta, Pivot Bio, Ginkgo Bioworks and Syngenta, among others.
- Headquarter Beijing, China
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website bluepha.com
- Social LinkedIn X
- Total Equity Funding$133.02M (USD)
in 8 rounds
- Latest Funding Round$58.64M (USD), Series B
Feb 2023
- InvestorsSVB
& 16 more
Funding Insights of Bluepha
Bluepha has successfully raised a total of $133.02M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $58.64 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $133.02M
- Total Rounds 8
- Last Round Series B β $58.64M
- First Round $726,694
(Feb 2017)
- Investors Count 17
All 8 funding rounds of Bluepha with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $73.3M | Debt – Conventional | β | β | |
| Feb 2023 | $58.64M | Series B | β | Zhongping Capital | |
| Jan 2022 | – | Series B | β | Country Garden, Genesis Capital | |
| Aug 2021 | $66.4M | Series B | β | Country Garden Ventures Capital | |
| May 2020 | – | Series A | β | Green Pine Capital Partners | β |
| Nov 2019 | $5.7M | Series A | β | Qianhai Ark Asset Management, Frees Fund | β |
| May 2018 | $1.56M | Seed | β | Frees Fund, Shenzhen Lihe Carrier Venture Capital | β |
| Feb 2017 | $726,694 | Seed | β | Frees Fund | β |
17 investors in total: 17 institutional.
Investors in Bluepha
Bluepha has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, China Merchants Bank and China Renaissance Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | zpcapital.cn | - | |
Financial services are provided by Huanghai Financial Holdings in China. | – | jshhjkjt.com | Yancheng, China | |
Tech focused VC firm investing in early stage companies in the US & China | – | freesvc.com | Beijing, China | |
Growth capital investments are managed by this private equity fund. | – | gcfunds.com | Beijing, China | |
- | – | zhongpingcapital.com | - | |
Investments in UK tech firms are made by GL Ventures. | – | gl.ventures | San Francisco, United States | |
A venture capital firm focused on biotech innovation investments. | 2018 | trinity-fund.com | Beijing, China | |
Venture capital investments are made in technology and consumer sectors. | 2019 | cgvcap.com | Shenzhen, China | |
M&A advisory, asset management firm, and private equity fund focused on multiple sectors | 2005 | huaxing.com | Chaoyang, China | |
Early- and growth-stage investments are directed toward hard technology sectors. | – | pinevc.com.cn | Beijing, China |
Investor details for Bluepha
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bluepha
6 people are tracked at Bluepha (6 in leadership).
| Name | Role | Group |
|---|---|---|
Yihao Zhang | Director, Domestic Fulfillment | Leadership |
Haoqian Zhang | Co-Founder and CEO | Leadership |
Hao Jiang | Vice President | Leadership |
Xinyu Liu | Assistant To Chief Executive Officer | Leadership |
Alex Yu | Director Of Marketing | Leadership |
Jie Li | Marketing Director | Leadership |
Complete people profiles for Bluepha
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Bluepha
3 dated milestones of Bluepha across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Bluepha is founded.
- Funding First funding round of $727K.
- Funding Latest funding round, Series B, of $58.6M.
Competitors of Bluepha
Bluepha operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Inscripta, Pivot Bio, Ginkgo Bioworks and Syngenta, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| inscripta.io | 2015 | Helsinki, Finland | $853,384 | – | Speech recognition solutions are provided by Inscripta for healthcare professionals. | |
| pivotbio.com | 2010 | Berkeley, United States | $618.08M | 256 | Nitrogen-fixing microbes for corn crop nutrition are developed and applied. | |
| ginkgobioworks.com | 2008 | Boston, United States | $795.75M | 1,218 | Gene editing-based cultured ingredients are provided for agriculture. | |
| syngenta.com | 2000 | Basel, Switzerland | – | – | Crop protection solutions and hybrid seeds are provided for farming. | |
| asimov.com | 2017 | Boston, United States | $209.4M | 87 | Provider of integrated suite for advanced genetic design and manufacturing | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed competitors of Bluepha
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bluepha
Complete news archive for Bluepha
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Bluepha
10 companies that operate in the same segment as Bluepha (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Bluepha
Bluepha was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Bluepha is headquartered in Beijing, China.
Bluepha is a funded company, having raised a total of $133.02M across 8 funding rounds to date. The company's 1st funding round was a Seed of $726.69K, raised on Feb 2017.
Bluepha was founded in 2016 in Beijing, China, and operates within the synthetic biology sector. Microbial manufacturing technology is utilized to create bio-based products applicable to industries such as consumer goods, healthcare, specialty chemicals, agriculture, and electronics. Development efforts focus on biomaterials that support diverse applications across these fields.
Bluepha has 17 investors. Key investors include SVB, China Merchants Bank, China Renaissance Group, η’§ζ‘ε, and Zhongping Capital.